CellVec seeks to advance clinical gene therapy through the innovative development and manufacturing of viral gene delivery vectors.
To ensure patient safety and fitness for purpose, we are committed to maintaining quality and regulatory compliance to rigorous standards (FDA and EU), while supporting our clients through commercial supply and licensing of their products. Our scientists are leading subject-matter experts and active participants in governmental advisory groups.
The CellVec team is made up of individuals experienced in a broad range of disciplines including:
Vector construct design
GMP manufacturing of vectors
Supply chain management
CellVec’s founders, Dr Lim ZiYi and Dr Lucas Chan, met at King’s College, London Dr Lim was then undergoing his specialist training in haemato-oncology at King’s College Hospital, while Dr Chan was in the early stages of his career developing the research and manufacturing platform for cell and gene therapy at King’s Clinical Research Facility. During their tenure in London, Dr Lim helped develop the haematology department into one of Europe’s largest allogenic haematopoietic stem cell transplant centres, while the manufacturing division of the Facility that Dr Chan oversaw became the epicentre for viral vector manufacturing in Europe.
Stirred by the rising incidence of cancer in Asia, Dr Lim and Dr Chan decided that it was time to return to their home region and contribute to the development of novel cancer therapies for the growing population-in-need in Asia.